SWOG clinical trial number
S9714

A Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Taxol in Stage IIIB & IV BAC
Activated
05/15/1997
Closed
03/15/2000

Research committees

Lung Cancer

Publication Information Expand/Collapse

2005

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

HL West;JJ Crowley;RB Vance;WA Franklin;RB Livingston;SR Dakhil;JK Giguere;SE Rivkin;MJ Kraut;K Chansky;DR Gandara Annals of Oncology 16:1076-1080

2004

Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition

DR Gandara;H West;K Chansky;AM Davies;DHM Lau;J Crowley;PH Gumerlock;FR Hirsh;WA Franklin Clinical Cancer Research 10 (Suppl):4205s-4209s

2003

EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung spore tissue samples.

WA Franklin;PH Gumerlock;J Crowley;K Chansky;HJ West;DR Gandara Proc of the American Society of Clinical Oncology 22:620(#2493)

2001

A phase II Southwest Oncology Group trial (S9714) utilizing paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma of the lung (BAC).

RB Vance;JJ Crowley;RB Livingston;DR Gandara Proc of the American Society of Clinical Oncology 20:336a(#1340)

2000

Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC)

RB Vance;JJ Crowley;D Gandara Lung Cancer 29(Suppl.2):7(#16)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase